Nordic AML Group

CCBIO Seminar – Mika Kontro - Functional Screening for Precision Medicine Approaches in AML
2024-03-21 14:30 - 15:30 (Europe/Paris)
Dr. Mika Kontro will discuss the methods for personalizing AML therapies using functional screening. He will provide an overview of the current data implementation and share insights from ongoing prospective trials employing functional screening. Furthermore, Dr. Kontro will focus on the VenEx trial, which utilizes ex vivo drug sensitivity testing to identify AML patients who can benefit from the azacitidine-venetoclax regimen.
More info can be found on this link.
Join via Zoom using this link.
No registration necessary.

Nordic AML 'poster walk' post-ASH
2024-03-12 15:00 - 17:00
Nordic AML posters at ASH 2023 – Webinar – 2024-03-12 – 15:00-16:20 (CET)
Join us for a webinar where we delve into the intricacies of showcased Nordic AML posters at the latest ASH Annual Meeting in December 2023. Here we aim for an opportunity to gain valuable insights, connect with peers, and stay at the forefront of AML innovation.

Join via Zoom: https://uu-se.zoom.us/j/63956689621

Tentative agenda (updated 2024-03-04)
15:00 – 15:05 – Welcome
15:05 – 15:15 – Elory Leonard, Stockholm, Sweden
Protective Function of Human Skin Mesenchymal Niches for Acute Myeloid Leukemia-Initiating Stem Cells
15:15 – 15:25 – Ida Vänttinen, Helsinki, Finland
Targeting Venetoclax Resistance in TP53-Mutated Acute Myeloid Leukemia
15:25 – 15:35 – Claudia Schöllkopf, Copenhagen, Denmark
Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
15:35 – 15:45 – Sofie Johansson Alm, Gothenburg, Sweden
Deep Sequencing Is a Widely Applicable Tool for Relapse Prediction in Acute Myeloid Leukemia with Mutated NPM1
15:45 – 15:55 – Øystein Sefland, Bergen, Norway
Intradermal Vaccination with Vididencel in MRD+ AML-Patients Leads to Increase in Antigen Presenting Cells and T-Cells to the Injection Site, Visualized Using Imaging Mass Cytometry, Showing Local Immune Cell Interactions Leading to Systemic Immune Responses
15:55 – 16:05 – Hanna Duàn, Helsinki, Finland
Primary Acute Myeloid Leukemia Cells Trigger Distinct Activation Patterns in Expanded NK Cells
16:05 – 16:15 – Somadri Ghosh, Lund, Sweden
H2-K1 on MLL-AF9 Leukemia Cells Facilitates the Escape of NK Cell-Mediated Immune Surveillance
16:15 – 16:25 – Jonas Bouhlal, Helsinki, Finland
High-Throughput Screens Identify NEDD8 Inhibition As a Strategy to Augment Natural Killer Cell Cytotoxicity Against Blood Cancers
16:25 – 16:30 – Closing remarks

Arranged by the NAMLG Educational Working Group (namlgewg@gmail.com)

Early Response Evaluation by Single-Cell Signaling Profiling in AML
2024-01-25 16:00 - 17:00
Webinar to be held January 25 at 16:00
This is in Standard Biotools’ (former Fluidigm) Scientist in the Spotlight series.
More info and registration on this link.
Hear about:
Insights into AML response: Discover the initial signaling response to standard induction chemotherapy in a cohort of 32 AML patients.

Predicting 5-year survival: Learn about the significant predictors of patient 5-year overall survival in this cohort, specifically the reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation.

Importance of signaling pathways: See how RNA sequencing and proteomics confirm the mass cytometry data and highlight the potential for this assay to be used in the future of precision oncology.

NAMLG TWG Meeting - I - 24-01-2024 15:30-16:30 CET
2024-01-24 15:30 - 16:30
Link and passcode for Teams meeting sent separately.
Agenda:

Update on potential LD-VenEx amendment trial comparing poDEC/LD-VenEx vs. AZA/LD-VenEx (5 min + 10 min discussion).
NAMLG – platform trial structure concept (5 min): Infrastructure with standing collaboration contracts (clinical trial agreement – CTA) and data processing agreements (DPAs) applicable for all types of trials. This would allow to open trials at one Nordic sponsor site and recruit pts from all Nordic Sites without the requirement to establish new CTAs / DPAs for each trial with individually. Ultimately, this will establish the NAMLG as partner for pharma-sponsored trials as well as to obtain funding for IIT.
List/overview of ongoing, already planned, and potential future AML trials in the Nordics.
Presentation and discussion of ongoing and potential novel AML trials

Martin Jädersten – Salvage Treatment + HU (5 min + 5 min discission
Oxcia: Presentation of MAATEO Karonudib + Dauno for RR AML (7 min+ 3 min discussion)
Trials suggested in previous mail by Bjørn Tore Gjertsen (6 min + 4 min discussion)

Webinar - Immunotherapy: a new perspective for AML maintenance treatment?
2023-12-06 15:30 - 16:30
Agenda
[Post updated 2024-03-16]
Download a recorded version of the webinar using this link.
Find the HCP guide for Ceplene on this link.
Ceplene can be ordered with the Nordic item number (Vnr.) 46 54 33, through:
Oriola in Sweden
TMJ in Denmark
Your local wholesaler, Apotek 1, NMD and Alliance in Norway
———————————————
AML patients not candidates to allotransplant: relapse risk and therapeutics (Pr Bjorn Gjertsen)
Immunotherapy with Histamine dihydrochloride in association with low-dose interleukin-2 (HDC/IL-2) for relapse prevention (Pr Kristoffer Hellstrand)
Conceivable indications of HDC/IL-2 for post-remission in AML? (Pr Bjorn Gjertsen, Dr Martin Jädersten, Dr Lovisa Wennström)
For more info, click here.
For registration, click here.

Myeloid Neoplasia StemCellTransplant (MNSCT) Nordic workshop
2023-11-30 12:00 - 21:00
We are thrilled to invite you all to the first MNSCT workshop. The program is planned by a scientific committee from the Swedish-Norwegian BMT-group and the Swedish AML-group. The overarching aim of this meeting is to stimulate discussions around topics within the Nordic community.
Please register for this event using this link (deadline 2023-10-27).
Click here for more information and the program.
The workshop is supported by medac Nordics.

Nordic AML webinar
2023-11-08 08:00 - 17:00
Thank you to all participants for taking part in the Nordic AML webinar 2023-11-08. For a recording of the webinar use this link.

MRD webinar
2023-10-10 08:00 - 17:00
Thank you to the panelists of our MRD webinar 2023-10-10. For a recording of the webinar use this link.

Nordic AML Meeting 2023
2023-08-24 - 2023-08-25 | Radisson BLU Royal Hotel, Bergen, Norway
Registration
Day 1: Thursday August 24, 2023
09:45-10:00: Welcome and Opening: Bjørn Tore Gjertsen (Chair, Nordic AML Group)
Session 1: Chairs: Bjørn Tore Gjertsen, Jeffrey Tyner
10:00-10:30: NAMLG Keynote Lecture
Sören Lehmann: Chromatin organization – the next step in the characterization of AML
10:30-10:50: Jorrit Enserink: Drug sensitivity Screen in AML undergoing intensive chemotherapy
10:50-11:10: Krister Wennerberg: Repurposing through drug sensitivity screen in AML
11:10-11:30: Caroline Heckman: Contextual factors in drug sensitivity screen
11:30-11:50: Päivi Östling: Harmonization of Drug sensitivity Screen
Session 2: Chair: Mika Kontro, Kim Theilgaard-Mönch
11:50-12:20: Martin Jädersten: Real world use of venetoclax
12:20-12:40: Kim Theilgaard-Mönch: Interim analysis of the NAMLG trial LD-VenEx
12:40-13:30: NAMLG Keynote Lecture
Daniel A Pollyea: Venetoclax in AML: Current state of the art and future development
13:30-14:30: LUNCH BREAK
Session 3: Chairs: Sören Lehmann, Oscar Brück
14:30-14:50: Tom Erkers: Data driven hallmarks in AML
14:50-15:10: Thoas Fioretos: Harnessing the Power of Genomics for Improved Precision Medicine
15:10-15:40 COFFEE BREAK
Session 4: Chairs: Bjørn Tore Gjertsen, Karl-Johan Malmberg
15:40-16:10: Mohn Research Centre for Regenerative Medicine (MRCRM) Keynote Lecture
Gunnar Kvalheim: WT1/PRAME RNA-loaded dendritic cell vaccine in AML
16:10-16:30: Karl-Johan Malmberg: NK immunotherapy in AML
16:30-16:50: Sébastien Walchli: CAR T in AML
18:10-19:15 RECEPTION IN HAAKONSHALLEN, BERGEN MUNCIPALITY
19:45 CONFERENCE DINNER
______________________________________________________________________
Day 2: Friday August 25, 2023
Session 5: Chairs: Anne-Sophie von Krogh, Marianne Tang Severinsen
08:15-08:45: Gunnar Juliusson: Challenges of the new AML classifications and guidelines
08:45 – 09:00: Discussion
09:00 – 09:30: NAMLG Keynote Lecture
Gerwin Huls: AML therapy backbone and the future of targeted therapies
09:30 – 09:50: Hans Beier Ommen: Measurable residual disease monitoring
09:50 – 10:10: Marianne Tang Severinsen: Registries in AML and a Nordic cohort of AML
10:10 – 10:40: Oscar Brück: Data Lake and collection of data for real world epidemiology
10:40 – 11:10 COFFEE BREAK
Session 6: Chairs: Caroline Heckman, JJ Schuringa
11:10 – 11:40: NAMLG Keynote Lecture
J.J. Schuringa: Tumor-stromal interactions in AML
11:40 – 12:00: Mika Kontro: Novel macrophage re-programmer bexmarilimab in myeloid malignancies
12:00 –12:30: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Jeffrey Tyner: Big data for novel therapeutic strategies in myeloid malignancies
12:30 – 13:30: LUNCH BREAK
Session 7: Chairs: James Lorens, Krister Wennerberg
13:30 – 13:45: James Lorens: Axl as therapeutic target in cancer
13:45 – 14:15: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Sonia Loges: AXL in AML
14:15 – 14:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Uwe Platzbecker: Bemcentinib and Axl in MDS and AML.
Session 8: Chairs: Jean Christoph Bourdon; Andrea Lenartova
14:45 – 15:05: Jean Cristoph Bourdon: p53 and its isoforms in cancer
15:05 – 15:45: CCBIO Keynote Lecture – Centre for Cancer Biomarker UiB
Eva Hellström-Lindberg: TP53 mutations in MDS and AML
15:45 – 16:15 COFFEE BREAK
Session 9: Chair: Pia Ettala, Vladimir Lazarevic
16:15 – 16:45: Martin Höglund: The therapeutic landscape in the Nordics: fit and unfit patients in a regional collaboration
16:45 – 17:00: Closing remarks: Mika Kontro, Secretary, NAMLG
Registration
